Pathophysiology of fibrinolysis

P. J. DECLERCK, I. JUHAN-VAGUE,* J. FELEZt & B. WIMANS From the Centre for Molecular and Vascular Biology. University Leuven. Leuven. Belgium. the *Laboratory of Haernatology. Universitg Hospital Tirnone. Marseille. France. the tDepartrnent of Cellular Receptors. Institute o/ Oncological Research. Barcelona. Spain, and the $Department of Clinical Chertiistry. Karolinska Hospital. Stockholm. Sweden

[1]  富田 勝郎,et al.  骨軟部腫瘍における Type 1 Plasminogen Activator Inhibitor(PAI-1)の発現と遠隔転移について , 1995 .

[2]  S. Thompson,et al.  Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[3]  M. Alessi,et al.  Plasminogen Activator Inhibitor 1 and Atherothrombosis , 1993, Thrombosis and Haemostasis.

[4]  W. Wijns,et al.  Regional wall motion abnormalities in stunned and hibernating myocardium. , 1993, European heart journal.

[5]  G. Bergonzelli,et al.  Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[6]  A. Henney,et al.  The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. , 1993, The Journal of biological chemistry.

[7]  Teizo Fujita,et al.  Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria , 1993, Cell.

[8]  J. Mcdonagh,et al.  Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. , 1993, Blood.

[9]  ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. , 1993, European heart journal.

[10]  A. Shapiro,et al.  Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. , 1992, The New England journal of medicine.

[11]  J. Jansson,et al.  von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death , 1992, British heart journal.

[12]  D. Loskutoff,et al.  Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Manson,et al.  Baseline Fibrinolytic State and the Risk of Future Venous Thrombosis: A Prospective Study of Endogenous Tissue‐Type Plasminogen Activator and Plasminogen Activator Inhibitor , 1992, Circulation.

[14]  E. Kruithof,et al.  Hypofibrinolysis in Patients with a History of Idiopathic Deep Vein Thrombosis and/or Pulmonary Embolism , 1992, Thrombosis and Haemostasis.

[15]  N. E. Hansen,et al.  The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. , 1992, Blood.

[16]  M. Borowitz,et al.  Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. , 1992, Blood.

[17]  K. Huber,et al.  A Decrease in Plasminogen Activator Inhibitor-1 Activity after Successful Percutaneous Transluminal Coronary Angioplasty Is Associated with a Significantly Reduced Risk for Coronary Restenosis , 1992, Thrombosis and Haemostasis.

[18]  T. Shigekiyo,et al.  Type I Congenital Plasminogen Deficiency Is not a Risk Factor for Thrombosis , 1992, Thrombosis and Haemostasis.

[19]  J. Loo.  Predictive value of hemostatic variables in cardiovascular disease , 1992 .

[20]  B. Boneu,et al.  Comparison of the fibrinolytic response to 10 minutes venous occlusion in males with and without antecedent of deep vein thrombosis. , 1991, Thrombosis research.

[21]  K. Robbins,et al.  Abnormal Plasminogen Maywood I , 1991, Thrombosis and Haemostasis.

[22]  R. Ware,et al.  Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. , 1991, The New England journal of medicine.

[23]  H. Büller,et al.  Deep Vein Thrombosis and Fibrinolysis , 1991, Thrombosis and Haemostasis.

[24]  M. Prins,et al.  A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. , 1991, Archives of internal medicine.

[25]  M. Prins,et al.  A critical review of the relationship between impaired fibrinolysis and myocardial infarction. , 1991, American heart journal.

[26]  M. Ploug,et al.  Protein Structure and Membrane Anchorage of the Cellular Receptor for Urokinase-Type Plasminogen Activator , 1991, Seminars in thrombosis and hemostasis.

[27]  R. McFall,et al.  Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. , 1991, The Journal of biological chemistry.

[28]  K. Hajjar,et al.  Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. , 1991, The Journal of biological chemistry.

[29]  J. Jansson,et al.  Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. , 1991, European heart journal.

[30]  E. Kruithof,et al.  A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. , 1991, Blood.

[31]  A. Henney,et al.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[32]  U. Smith,et al.  Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. , 1990, Metabolism: clinical and experimental.

[33]  A. Hamsten,et al.  The Fibrinolytic Enzyme System and Its Role in the Etiology of Thromboembolic Disease , 1990, Seminars in thrombosis and hemostasis.

[34]  N. Aoki,et al.  Impaired secretion of mutant alpha 2-plasmin inhibitor (alpha 2 PI-Nara) from COS-7 and HepG2 cells: molecular and cellular basis for hereditary deficiency of alpha 2-plasmin inhibitor. , 1990, Blood.

[35]  G. Cross,et al.  Glycolipid anchoring of plasma membrane proteins. , 1990, Annual review of cell biology.

[36]  W. Rosse,et al.  Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. , 1990, Blood.

[37]  M. G. Low.  The glycosyl-phosphatidylinositol anchor of membrane proteins. , 1989, Biochimica et biophysica acta.

[38]  N. Aoki,et al.  Hereditary alpha 2-plasmin inhibitor deficiency caused by a transport-deficient mutation (alpha 2-PI-Okinawa). Deletion of Glu137 by a trinucleotide deletion blocks intracellular transport. , 1989, The Journal of biological chemistry.

[39]  Raymond,et al.  Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. , 1989, The Journal of clinical investigation.

[40]  D. Collen,et al.  Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis , 1989 .

[41]  L. Lund,et al.  The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene. , 1988, Nucleic acids research.

[42]  H. Sue-Ling,et al.  Comparison of oral stanozolol with low dose heparin in prevention of deep venous thrombosis in high risk patients after elective major abdominal surgery , 1988 .

[43]  J. Paramo,et al.  Preoperative Identification of Patients at High Risk of Deep Venous Thrombosis Despite Prophylaxis in Total Hip Replacement , 1988, Thrombosis and Haemostasis.

[44]  G. Dooijewaard,et al.  alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. , 1987, The Journal of clinical investigation.

[45]  L. Nelles,et al.  Alpha 2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. , 1987, Science.

[46]  G. Bergonzelli,et al.  MINI PLASMINOGEN-LIKE MOLECULE IN SEPTIC PATIENTS , 1987, Thrombosis and Haemostasis.

[47]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[48]  J. Jespersen,et al.  A Selective Depression of Tissue Plasminogen Activator (t-PA) Activity in Euglobulins Characterises a Risk Group Among Survivors of Acute Myocardial Infarction , 1987, Thrombosis and Haemostasis.

[49]  M. Alessi,et al.  Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis , 1987, Thrombosis and Haemostasis.

[50]  I. Scharrer,et al.  Investigation of a Congenital Abnormal Plasminogen, Frankfurt I, and Its Relationship to Thrombosis , 1986, Thrombosis and Haemostasis.

[51]  E. Plow,et al.  The fibrinolytic system in man. , 1986, Critical reviews in oncology/hematology.

[52]  E. Kruithof,et al.  Release of vascular plasminogen activator (v‐PA) after venous stasis: electrophoretic—zymographic analysis of free and complexed v‐PA , 1985, British journal of haematology.

[53]  S. Manabe,et al.  Homozygous protein C deficiency combined with heterozygous dysplasminogenemia found in a 21-year-old thrombophilic male. , 1985, Thrombosis research.

[54]  B. Wiman,et al.  Relationship between preoperative status of the fibrinolytic system and occurrence of deep vein thrombosis after major abdominal surgery. , 1985, Thrombosis research.

[55]  L. Tengborn,et al.  Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. , 1985 .

[56]  B. Wiman,et al.  A novel fast inhibitor to tissue plasminogen activator in plasma, which may be of great pathophysiological significance. , 1985, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[57]  M. Kundi,et al.  Impaired Fibrinolytic Capacity Predisposes for Recurrence of Venous Thrombosis , 1984, Thrombosis and Haemostasis.

[58]  F. España,et al.  Inherited Fibrinolytic Disorder Due to an Enhanced Plasminogen Activator Level , 1984, Thrombosis and Haemostasis.

[59]  Y. Sakata,et al.  Plasminogens Tochigi II and Nagoya: two additional molecular defects with Ala-600----Thr replacement found in plasmin light chain variants. , 1984, Journal of biochemistry.

[60]  D. Collen,et al.  Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. , 1984, Thrombosis research.

[61]  J. Soria,et al.  Plasminogen Paris I: congenital abnormal plasminogen and its incidence in thrombosis. , 1983, Thrombosis research.

[62]  B. Bennett,et al.  A new life-long hemorrhagic disorder due to excess plasminogen activator , 1983 .

[63]  B. Bennett,et al.  A new life-long hemorrhagic disorder due to excess plasminogen activator. , 1983, Blood.

[64]  K. Robbins,et al.  Human Plasminogen Variant Chicago III , 1982, Thrombosis and Haemostasis.

[65]  Y. Sakata,et al.  Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[66]  K. Gohchi,et al.  Abnormal plasminogen, a case of recurrent thrombosis. , 1981, Thrombosis research.

[67]  Y. Sakata,et al.  Molecular abnormality of plasminogen. , 1980, The Journal of biological chemistry.

[68]  J. Conard,et al.  α2-Antiplasmin Assay: Amidolytic and Immunological Method. Critical Evaluation. Results in a Clinical Material , 1980 .

[69]  K. Robbins,et al.  Physiological activation of the human fibrinolytic system. Isolation and characterization of human plasminogen variants, Chicago I and Chicago II. , 1979, The Journal of biological chemistry.

[70]  Y. Sakata,et al.  Congenital Deficiency of α2-Plasmin Inhibitor Associated with Severe Hemorrhagic Tendency , 1979 .

[71]  J. Takamatsu,et al.  α2-PLASMIN-INHIBITOR DEFICIENCY (MIYASATO DISEASE) , 1978, The Lancet.

[72]  Y. Sakata,et al.  Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. , 1978, The Journal of clinical investigation.

[73]  Aoki Nobuo,et al.  The α2-plasmin inhibitor levels in liver diseases , 1978 .

[74]  H. Noppa,et al.  Determination of fast-acting plasmin inhibitor (alpha2-antiplasmin) in plasma from patients with tendency to thrombosis and increased fibrinolysis. , 1978, Haemostasis.

[75]  J A Anderson,et al.  Preoperative prediction of postoperative deep vein thrombosis. , 1976, British medical journal.

[76]  I. Nilsson,et al.  Phenformin and ethyloestrenol in recurrent venous thrombosis. , 2009, Acta medica Scandinavica.

[77]  M. Verstraete,et al.  Intravascular coagulation in liver disease. , 1974, Annual review of medicine.

[78]  I. Nilsson,et al.  Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis. , 1972, Acta chirurgica Scandinavica.

[79]  R. D. Davis,et al.  Low plasminogen levels and liver disease. , 1969, American journal of clinical pathology.